Navigation Links
Alzheimer's Drug Discovery Foundation Supports ADispell Technology with a Grant to Advance Novel Drug Candidates for Alzheimer's Disease
Date:3/21/2011

NEW YORK, March 21, 2011 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced that it has awarded a grant of $170,750 to ADispell Inc. to develop small molecule drugs designed to halt the progression of cognition loss that occurs with Alzheimer's Disease.

(Logo: https://photos.prnewswire.com/prnh/20090805/DC57332LOGO)

ADispell has licensed technology from Cornell University to develop neuroprotective drug candidates targeting a novel site on the nicotinic acetylcholine receptor which is critical for memory processing.  These new drug candidates should improve symptoms, slow the progression of Alzheimer's disease and potentially reverse the course of the disease.  The ADDF's grant will fund a significant pharmacological proof-of-concept program to validate the effects of these compounds in animal models.  

"We are really grateful that the ADDF has found value in our innovations and is supporting our work to move this important technology forward," said Stephen Curry, Ph.D., Chief Executive Officer for ADispell. "We have identified a novel drug target that improves mental performance and compounds that act on that target to improve brain function. These funds will allow us to gain a better understanding of how the compounds affect diseases that cause cognition loss."

"ADispell's unique approach to targeting memory loss holds great promise as a treatment for Alzheimer's disease," said Howard Fillit, M.D., Executive Director for the ADDF.  "The ADDF's investment in ADispell at this critical proof-of-concept stage has the potential to advance their program to the next stage of development."

There are estimated to be more than 5 million patients in the United States and more than 35 million individuals worldwide suffering from Alzheimer's disease.  The disease is believed to have an annual impact of $172 billion on health care in the United States and is projected to increase rapidly in the near future.

About the Alzheimer's Drug Discovery Foundation (www.AlzDiscovery.org)  

The Alzheimer's Drug Discovery Foundation (ADDF) is the only public charity whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. Since 1998, the ADDF has granted more than $45 million to fund over 325 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 17 countries. 

About ADispell (www.adispell.com)  

ADispell Inc. is a biotechnology development firm with proprietary technology that acts on brain neurons to treat and prevent the cognitive loss caused by Alzheimer's and other diseases. The company was founded in 2009 and has operations in Rochester, NY and Ithaca, NY. Learn more at www.adispell.com.


'/>"/>
SOURCE Alzheimer's Drug Discovery Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GE Discovery ST Installed at Imaging Healthcare Specialists
2. Lixte Biotechnology Holdings, Inc. Awarded Grant Under Qualifying Therapeutic Discovery Project from the U. S. Government
3. Dave Anderson and William Thomsen Join SRI Internationals Center for Advanced Drug Research to Lead Programs in Proteomics and Metabolic Disease Drug Discovery
4. Reportlinker Adds Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies
5. Caliper Life Sciences IVIS® Optical Imaging System Adoption Surpasses 1000 Units: Validated Drug Research, Discovery and Development Tool Enables Advances in Personalized Medicine
6. BioSurplus Selected to Liquidate Discovery Laboratory Equipment
7. PTC Therapeutics and Parent Project Muscular Dystrophy Advance Drug Discovery Program to Improve Heart Function in Duchenne/Becker Muscular Dystrophy Patients
8. Reportlinker Adds The Drug Discovery Outsourcing Market
9. Collaborative Drug Discovery Receives New Funding to Support Tuberculosis Drug Discovery Screening Efforts and Industrial-Academic Collaborations
10. TREVENTIS Corporation Founder Wins Prestigious Discovery Award
11. Reportlinker Adds Innovative Drug Discovery in Emerging Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Oct. 12, 2017 AVACEN Medical , Inc. ... with their  2017 New Product Innovation Award for Its ... primary and secondary medical device market research by Frost & ... first-to-market OTC, drug-free pain relief product, the AVACEN 100, offers ... treating fibromyalgia widespread pain. ...
(Date:10/12/2017)... West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today announced that it will release third-quarter ... October 26, 2017, and will follow with a conference ... 9:00 a.m. Eastern Time. To participate on the call, ... ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ... on fulfilling the promise of precision medicine, today announced ... joined Caris, Precision Oncology Alliance™ (POA) as its 17 ... centers, the St. Jude Crosson Cancer Institute will help ... the use of tumor profiling, making cancer treatment more ...
Breaking Medicine Technology:
(Date:10/13/2017)... N.Y (PRWEB) , ... October 13, 2017 , ... Lori ... became a member of ElderCounsel, a national organization of elder law and special needs ... changing laws and rules. It also provides a forum to network with elder law ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids ... Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, ... run is geared towards children of all ages; it is a non-competitive, non-timed event, ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
Breaking Medicine News(10 mins):